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Aim The aim of this study was to evaluate whether coronary artery disease (CAD) severity exerts a gradient of risk in patients
with aortic stenosis (AS) undergoing transcatheter aortic valve implantation (TAVI).
Methods
and results
A total of 445 patients with severeAS undergoingTAVI were included into a prospective registrybetween2007 and 2012.
The preoperative SYNTAX score (SS) was determined from baseline coronary angiograms. In case of revascularization
prior to TAVI, residual SS (rSS) was also determined. Clinical outcomes were compared between patients without CAD
(n ¼ 158), patients with low SS (0–22, n ¼ 207), and patients with high SS (SS.22, n ¼ 80). The pre-specified primary
endpoint was the composite of cardiovascular death, stroke, or myocardial infarction (MI). At 1 year, CAD severity was
associated with higher rates of the primary endpoint (no CAD: 12.5%, low SS: 16.1%, high SS: 29.6%; P ¼ 0.016). This was
driven by differences in cardiovascular mortality (no CAD: 8.6%, low SS: 13.6%, high SS: 20.4%; P ¼ 0.029), whereas the
risk of stroke (no CAD: 5.1%, low SS: 3.3%, high SS: 6.7%; P ¼ 0.79) and MI (no CAD: 1.5%, low SS: 1.1%, high SS: 4.0%;
P ¼ 0.54) was similar across the three groups. Patients with high SS received less complete revascularization as indicated
by a higher rSS (21.2+12.0 vs. 4.0+4.4, P, 0.001) compared with patients with low SS. High rSS tertile (.14) was
associatedwithhigher ratesof theprimaryendpoint at1year (noCAD:12.5%, lowrSS: 16.5%,high rSS: 26.3%,P ¼ 0.043).
Conclusions Severity of CAD appears to be associated with impaired clinical outcomes at 1 year after TAVI. Patients with SS .22
receive less complete revascularization and have a higher risk of cardiovascular death, stroke, or MI than patients
without CAD or low SS.
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Introduction
Coronary artery disease (CAD) and aortic valve stenosis (AS) fre-
quently co-exist.1 The common clinical occurrence is related at
least in part to a similar pathogenesis.2 Beyond age-related
degenerative changes, both disease entities are characterized by
active lesions with subendothelial accumulation of oxidized low-
density lipoproteins and inflammation with lymphocytes and macro-
phages which are responsible for disease progression.3,4 Moreover,
CAD and AS share several risk factors including age, male gender,
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arterial hypertension, hypercholesterolaemia, diabetes mellitus, and
chronic kidney disease.2 As a result,.50% of patients with severe AS
undergoing surgical aortic valve replacement (SAVR) or transcath-
eter aortic valve implantation (TAVI) have concomitant CAD.5 –12
The presence of CAD increases the risk for peri-procedural com-
plications and impairs long-term clinical outcomes after SAVR.5 –7
Whether CAD and its severity have prognostic implications
among elderly patients with severe AS undergoing TAVI is still a
matter of debate.8 –13 Of note, the extent and complexity of CAD
among patients with severe AS is quite variable. The SYNTAX
score (SS) is an anatomical risk score which allows to quantify the
extent and complexity of CAD, and has been shown to predict long-
term clinical outcomes among patients with CAD undergoing percu-
taneous coronary intervention (PCI).14– 16 The purpose of the
present study was to evaluate the impact of CAD severity as assessed




A total of 445 elderly patients with symptomatic severe AS undergoing
TAVI were included into a prospective registry at Bern University Hos-
pital (Bern TAVI Registry) between August 2007 and April 2012. Patients
referred for TAVI evaluation underwent interdisciplinary discussion
within the local, institutional Heart Team consisting of invasive cardiolo-
gists, and cardiovascular surgeons. The indication for TAVI was based on
patients’ clinical history, clinical status, anatomical suitability, and geriatric
assessment.17,18 Patients underwent implantation of the Medtronic Cor-
eValve bioprosthesis (Medtronic, Minneapolis, MN, USA), the Edwards
Sapien transcatheter heart valve (Edwards LifeSciences, Irvine, CA,
USA), or theSymetis Acurate TAaortic bioprosthesis (Symetis, Ecublens,
Switzerland) using the femoral, transapical, or subclavian access route as
previously described.17 The selected access route followed the principle
of the least invasive approach, based on the individual anatomical
characteristics as determined by contrast enhanced computed tomog-
raphy, angiography, and transthoracic or transoesophageal echocardiog-
raphy.19 Among patients with CAD, complete revascularization of
proximal coronary artery segments with a diameter stenosis ≥70%
was attempted by PCI. The latter was performed either in a scheduled
session prior to TAVI (staged PCI) or at the time of TAVI (concomitant
PCI). In case of concomitant PCI, patients underwent PCI followed by
TAVI during the same session. Revascularization strategies were based
on clinical presentation and coronary angiography findings since func-
tional methods of ischaemia detection have not been validated in patients
with severe AS. The study complied with the declaration of Helsinki, and
the registry was approved by the local ethics committee. All the patients
provided written informed consent to participate in the Bern TAVI Regis-
try with prospective follow-up assessment.
Angiographic analysis
All angiographic analyses were performed at the Core Angiographic La-
boratory of the Department of Cardiology at Bern University Hospital,
Bern, Switzerland. For the purpose of this study, baseline coronary angio-
grams of all patients were reviewed by two experienced invasive cardiol-
ogists who were trained in the assessment of SS and blinded to clinical
outcomes.20 Coronary artery disease was defined as the presence of
one or more lesions of the epicardial coronary arteries with≥50% diam-
eter stenosis in vessels ≥1.5 mm in diameter. For patients with CAD, SS
atbaseline—defined as SS prior to any PCI—was calculated by consensus
of the two readers using the SS algorithm (available at www.syntaxscore
.com).21 In case of disagreement, the opinion of a third reviewer was
obtained and final decision was achieved by consensus. For patients
with prior coronary artery bypass surgery (CABG), the CABG SS was
applied.22 For patients undergoing PCI, the extent and complexity of un-
treated CAD was determined by assessing residual SS (rSS)—defined as
SS of remaining CAD after PCI prior to TAVI.23 For patients not under-
going PCI rSS was considered equivalent to SS at baseline. The SS of 30
randomly selected cases were reassessed by the same readers 4 weeks
later, with evidence of a strong correlation in terms of reproducibility
(r ¼ 0.98).
Study endpoints and definitions
The pre-specifiedprimaryendpoint of the present study wasa composite
of ischaemic clinical outcomes—cardiovascular death, stroke, or myo-
cardial infarction (MI)—at 1 year. Secondary endpoints were the individ-
ual components of the primary endpoint, as well as all-cause death and
the composite of all-cause death, stroke, and MI. Acute kidney injury,
access site complications, and the Valve Academic Research Consortium
(VARC) safety endpoint were assessed. The definition of cardiovascular
death involved any death due to a proximate cardiac cause or a death of
unknown cause, as well as all procedure-related deaths and death caused
by non-coronary vascular conditions such as cerebrovascular disease,
pulmonary embolism, or other vascular disease. Peri-procedural MI
(≤72 h) wasdetermined as new ischaemic symptoms or signs in the pres-
ence of elevated cardiac biomarkers (i.e. two or more post-procedure
samples that were .6–8 h apart with a 20% increase in the second
sample and a peak value .10× the 99th percentile URL, or a peak
value .5× the 99th percentile URL with new pathological Q waves in
at least two contiguous leads).24 Spontaneous MI (.72 h) was deter-
mined in case of elevation of cardiac biomarkers (i.e. at least one value
.99th percentile URL) together with evidence of ischaemia.24 Major
stroke encompassed a rapid onset of focal or global neurological deficit
of≥24 h duration necessitating therapeutic intervention, or documenta-
tion of a new intracranial defect using MRI or CT-scan. Acute kidney
injury was defined according to a modified RIFLE classification and was
based upon changes in serum creatinine up to 72 h after the procedure.
Stage 3 kidney injury was considered in case of an increase in creatinine of
≥300% with an acute increase of at least 44 mmol/L. Moreover, patients
receiving any case of renal replacement therapy (haemodialysis, periton-
eal dialysis, or haemofiltration) during the index hospitalization or within
the first 30 days after the procedure are considered to meet stage 3
kidney injury irrespective of other criteria. All events were adjudicated
according to the VARC I definitions24 by a clinical event committee con-
sisting of invasive cardiologists and cardiac surgeons.
Clinical follow-up
Adverse events were assessed in hospital, and regular clinical follow-up
was performed at 1, 6, and 12 months by means of a clinical visit or a stan-
dardized telephone interview. All suspected events were adjudicated by
the clinical event committee. Baseline clinical and procedural character-
istics and all follow-up data were entered into a dedicated database, held
at an academic clinical trials unit (CTU Bern, Bern University Hospital,
Switzerland) responsible for central data audits and maintenance of the
database.
Statistical analysis
Patients were stratified into three groups according to the presence and
severity of CAD: patients without CAD, patients with low SS (0–22), and
patients with high SS (.22). Baseline characteristics and clinical
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outcomes werecomparedbetweengroups. Discretedatawere summar-
ized as counts and frequencies (%) and compared with ANOVAs,
whereas continuous data were presented as means+ SD and compared
with x2 tests.
Clinical outcomes at 30 and 1 year were expressed as counts or inci-
dence rates computed according to Kaplan–Meier analysis. Hazard
ratios were derived from Mantel-Cox log-rank for death, cardiovascular
death, stroke,MI, and the composites of these endpoints. Risk ratioswere
computed from Poisson regression with robust error variances for acute
renal failure, access site complications, and VARC safety endpoint.
Clinical outcomes at 1 year were also compared between: patients
without CAD, patients in the lower rSS tertiles (0–14), and patients in
the higher rSS tertile (.14).
A Cox multivariate regression analysis was performed to assess pre-
dictors of 1-year risk of the composite primary endpoint of cardiovas-
cular death, stroke, or MI, including in the model baseline SS .22 as
well as covariates known to be associated with these adverse events
(i.e. age, gender, diabetes, hypercholesterolaemia, peripheral vascular
disease, left ventricular ejection fraction). To assess reproducibility
of the SS assessment, the Pearson’s r correlation coefficient was used.
Analyses were performed using STATA version 12.1 (StataCorp,
College Station, TX, USA). P-values ,0.05 were considered statistically
significant.
Results
Out of 445 elderly patients with severeAS undergoing TAVI between
2007 and 2012, 158 patients (35.5%) had no CAD, 207 patients
(46.5%) had a low SS (0–22), and 80 patients (18.0%) had a high SS
(.22). Scheduled follow-up was completed in all patients, with a
mean follow-up duration of 258+ 146 days for the overall popula-
tion and no differences between groups (no CAD: 261+144 days,
low SS: 257+146 days, high SS: 254+ 149 days).
Baseline and procedural characteristics
Baseline clinical characteristics are summarized in Table 1. At base-
line, patients with higher SS were less frequently female (no CAD:
70%, low SS: 56%, high SS: 28%; P, 0.001). Increased CAD severity
was associated with diabetes mellitus (no CAD: 20%, low: SS 28%,
high SS: 36%; P ¼ 0.019), hypercholesterolaemia (no CAD: 43%,
low SS: 66%, high SS: 86%; P, 0.001), peripheral vascular disease
(no CAD: 12%, low SS: 23%, high SS: 31%; P ¼ 0.001), and reduced
left ventricular ejection fraction (no CAD: 53.7+ 15.0%, low SS:
52.7+14.6%, high SS: 47.4+14.7%; P ¼ 0.007). The mean aortic
valve area was larger (no CAD: 0.56+ 0.24 cm2, low SS: 0.61+
0.22 cm2, high SS: 0.67+ 0.21 cm2; P ¼ 0.003) and mean transaortic
valvular gradient lower (noCAD:46.9+18.2 mmHg, lowSS: 42.1+
15.9 mmHg, high SS: 38.3+ 15.0 mmHg; P ¼ 0.001) among patients
with higher SS. The Logistic EuroSCORE (no CAD: 19.5+ 11.1, low
SS: 23.7+13.8, high SS: 30.3+15.7; P, 0.001) and the STS score
(no CAD: 5.9+4.3, low SS: 7.0+5.5, high SS: 8.6+ 6.3; P ¼
0.001) were higher with increasing CAD extent and complexity.
Among patients with CAD, thosewith high SShad more frequently
prior MI, previous CABG and PCI, and where characterized by
morecomplex CADin termsof numberof vessels involved, presence
of small vessel disease, long lesions, bifurcation lesions, and type
B2/C lesions compared with patients with low SS. Procedural
characteristics were similar among all groups as summarized in
Table 2. Noteworthy, patients with high SS at baseline had higher
rSS compared with patients with low SS (4.0+4.4 vs. 21.2+ 12.0,
P, 0.001).
Clinical outcomes
Clinical outcomes through 1 year after TAVI are reported in Table 3.
At 30 days, similar findings were observed across the three groups
with respect to the primary endpoint (no CAD: 7.0%, low SS: 7.2%,
high SS: 10.0%; P ¼ 0.54), as well as the individual components car-
diovascular death (no CAD: 3.8%, low SS: 5.4%, high SS: 7.5%; P ¼
0.22), stroke (no CAD: 5.1%, low SS: 2.0%, high SS: 2.6%; P ¼ 0.19),
and MI (no CAD: 0.6%, low SS: 0.5%, high SS: 0%).
At 1 year, increased CAD severity was associated with higher rates
of the primary endpoint (no CAD: 12.5%, low SS: 16.1%, high SS:
29.6%; P ¼ 0.016). This was mainly driven by a difference in cardio-
vascular death (no CAD: 8.6%, low SS: 13.6%, high SS: 20.4%; P ¼
0.029), whereas the risk of stroke (no CAD: 5.1%, low SS: 3.3%,
high SS: 6.7%; P ¼ 0.79) and MI (no CAD: 1.5%, low SS: 1.1%, high
SS: 4.0%; P ¼ 0.54) was similar in all three groups. Rates of all-cause
mortality (no CAD: 16.9%, low SS: 19.6%, high SS: 26.1%; P ¼
0.16), and of the composite of all-cause mortality, stroke, and MI
(no CAD: 19.4%, low SS: 21.5%, high SS: 33.5%; P ¼ 0.071), were nu-
merically higher with increasing CAD severity, although statistically
not significant. Cumulative event rates of the primary endpoint and
cardiovascular mortality among patients without CAD, patients
with low SS, and patients with high SS are shown in Figures 1 and 2.
Of note, the 1-year risk of the primary endpoint was higher among
patients with high SS (HR: 2.24, 95% CI: 1.18–4.23, P ¼ 0.013) and
similar among patients with low SS (HR: 1.23, 95% CI: 0.68–2.21,
P ¼ 0.49) compared with patients without CAD.
Using multivariate analysis (Figure 3), left ventricular ejection frac-
tion (HR: 1.29, 95% CI: 1.11–1.51) emerged as the only independent
predictor of the primary endpoint at 1 year. Coronary artery disease
with SS.22wasassociatedwith an increasedriskof theprimaryend-
point without reaching statistical significance (HR: 1.68, 95% CI:
0.94–3.02, P ¼ 0.079).
Since 48.4% of patients with CAD underwent PCI prior to TAVI,
clinical outcomes were also compared according to rSS post-PCI
(Table 4). Although the range of rSS varied considerably for any
value of SS, a strong correlation was observed between SS and rSS
(Figure 4; Spearman’s rho ¼ 0.84, P, 0.001), indicating that patients
with high SS received less complete revascularization and therefore
had a higher extent and complexity of CAD after PCI prior to TAVI
compared with patients with low SS. The primary endpoint occurred
more frequently among patients in the higher rSS tertile (26.3%)
compared with patients in the lower rSS tertiles (16.5%) and patients
without CAD (12.5%, P ¼ 0.043).
Discussion
To the best of our knowledge, this is the first study to assess the
impact of CAD severity as quantified by the angiographic SS on clin-
ical outcomes among elderly patients with severe AS undergoing
TAVI, and has the following principal findings:
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Table 1 Baseline clinical characteristics
Overall (n5 445) No CAD (n5 158) CAD by SYNTAX-score P-value
Low (0–22) (n 5 207) High (>22) (n5 80)
Age, years 82.5+5.8 83.0+5.9 82.4+5.9 81.9+5.2 0.36
Female gender (%) 249 (56) 111 (70) 116 (56) 22 (28) ,0.001
Body mass index, kg/m2 26.1+4.9 25.7+4.9 26.4+5.1 25.9+4.2 0.38
Cardiac risk factors (%)
Diabetes mellitus 117 (26) 31 (20) 57 (28) 29 (36) 0.019
Insulin-treated 41 (9) 10 (6) 23 (11) 8 (10) 0.28
Hypercholesterolaemia 273 (61) 67 (43) 137 (66) 69 (86) ,0.001
Hypertension 362 (81) 122 (77) 173 (84) 67 (84) 0.25
Current smoker 44 (10) 14 (9) 22 (11) 8 (10) 0.85
Past medical history (%)
Previous stroke 35 (8) 10 (6) 20 (10) 5 (6) 0.42
PVD 92 (21) 19 (12) 48 (23) 25 (31) 0.001
Chronic obstructive pulmonary disease 79 (18) 31 (20) 34 (16) 14 (18) 0.71
Clinical features
Systolic pulmonary pressure, mmHg 51.3+17.2 50.7+17.2 52.0+17.3 50.6+17.0 0.73
Renal failure (%) 301 (68) 113 (72) 135 (65) 53 (66) 0.43
Atrial fibrillation (%) 128 (29) 53 (34) 59 (29) 16 (20) 0.10
LVEF, % 52.1+14.9 53.7+15.0 52.7+14.6 47.4+14.7 0.007
Aortic valve area, cm2 0.60+0.23 0.56+0.24 0.61+0.22 0.67+0.21 0.003
Mean transaortic gradient, mmHg 43.1+16.9 46.9+18.2 42.1+15.9 38.3+15.0 0.001
Symptoms (%)
NYHA I or II 154 (35) 54 (35) 74 (36) 26 (33) 0.90
NYHA III or IV 288 (65) 102 (65) 133 (64) 53 (67) 0.90
Coronary artery disease (%)
Prior MI 67 (15) 0 (0) 41 (20) 26 (33) ,0.001
Prior CABG 75 (17) 0 (0) 28 (14) 47 (59) ,0.001
Prior PCI 109 (24) 0 (0) 70 (34) 39 (49) ,0.001
Vessels diseased (%)
Left main 25 (9) – 6 (3) 19 (24) ,0.001
Left anterior descending 220 (79) – 141 (71) 79 (99) ,0.001
Left circumflex 159 (57) – 87 (44) 72 (90) ,0.001
Right coronary artery 170 (61) – 97 (49) 73 (91) ,0.001
Vein graft 38 (13) – 6 (3) 32 (40) ,0.001
Small vessel disease 16 (12) – 4 (4) 12 (29) ,0.001
Bifurcation lesions 53 (38) – 28 (29) 25 (60) 0.001
Long lesions 59 (42) – 34 (35) 25 (60) 0.009
Type B2 or C lesions 102 (73) – 64 (66) 38 (90) 0.003
Risk assessment
Baseline SYNTAX score 16.5+12.5 – 10.1+6.5 33.2+7.9 ,0.001
Logistic EuroSCORE 23.4+13.8 19.5+11.1 23.7+13.8 30.3+15.7 ,0.001
STS score 6.9+5.3 5.9+4.3 7.0+5.5 8.6+6.3 0.001
Antithrombotic therapy (%)
Aspirin 270 (61) 68 (43) 138 (67) 64 (81) ,0.001
Clopidogrel 86 (20) 13 (8) 50 (24) 23 (29) ,0.001
Oral anticoagulation 121 (27) 45 (29) 57 (28) 19 (24) 0.75
Values are n (%) or means+ SD. CABG,coronary artery bypass graft; CAD, coronary artery disease; LVEF, left ventricular ejection fraction; MI, myocardial infarction; NYHA,
New York Heart Association; PCI, percutaneous coronary intervention; PVD, peripheral vascular disease; STS, Society of Thoracic Surgeons.
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(1) coronary artery disease is present in two-thirds of elderly
patients with severe AS undergoing TAVI in routine clinical
practice;
(2) severity of CAD is associated with higher risk profiles at baseline
and impaired ischaemic clinical outcomes at1 yearamong elderly
patients with severe AS undergoing TAVI;
(3) patients with CAD and SS .22 undergoing TAVI are associated
with a higher risk of cardiovascular death, stroke, or MI at 1 year,
owing to a two-fold increased risk of cardiovascular mortality
compared with patients without CAD.
Coronary artery disease and AS share several pathophysiological
mechanisms which contribute to the coexistence of both disease en-
tities. Initiating factors of CAD and AS are similar and include the sub-
endothelial accumulation of oxidized low-density lipoprotein, and
recruitment of lymphocytes and macrophages resulting in local in-
flammatory reactions.3,25 These processes lead to extracellular
matrix formation, calcification, fibrosis, and endothelial dysfunction
which are accentuated by mechanical stress in both CAD and AS.
However, the larger accumulation of extracellular calcification and
the absence of smooth-muscle cells distinguish AS from CAD.4
Moreover,AS is characterizedby gradual but continuousprogression
with subsequent clinical events resulting from left ventricularoutflow
obstruction due to immobile leaflets.1 Conversely, CAD does not
follow a continuous and linear fashion but is characterized by
periods of relative quiescence followed by episodes of clinically ap-
parent or silent plaque rupture.26 Clinical events in patients with
CAD are related to myocardial ischaemia, typically as a consequence
of atherosclerotic plaque instability.26
In this seriesof445elderlypatientswithsevereASundergoingTAVI,
almost two-thirds (65%) of patients had evidence of CAD. Interesting-
ly, the severity of CAD was associated with major comorbidities at
baseline. Similarfindings were recently reported ina study investigating
CADamongpatients with severeASundergoingSAVR.5 In thepresent
study, we observed that the extent and complexity of CAD correlated
with baseline risk profiles reflecting a higher burden of atherosclerotic
disease. Indeed, patients with more severe CAD—as indicated
by higher SS—had more frequently prior ischaemic events, peripheral
vascular disease, hypercholesterolaemia, diabetes mellitus, and
impaired left ventricular function at baseline. The correlation of
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Table 2 Procedural characteristics
Overall (n 5 445) No CAD (n 5 158) CAD by SYNTAX-score P-value
Low (0–22) (n5 207) High (>22) (n5 80)
Access route (%) 0.44
Femoral 348 (78) 130 (82) 158 (76) 60 (75) 0.29
Apical 92 (21) 27 (17) 47 (23) 18 (23) 0.38
Subclavian 5 (1) 1 (1) 2 (1) 2 (3) 0.42
Valve type (%) 0.53
Medtronic core valve 240 (54) 91 (58) 106 (51) 43 (54) 0.48
Edwards Sapien valve 202 (45) 65 (41) 100 (48) 37 (46) 0.39
Symetis acurate TA 3 (1) 2 (1) 1 (0.5) 0 (0) –
Procedural specifications (%)
General anaesthesia 178 (42) 55 (37) 92 (46) 31 (41) 0.24
PCI 139 (31) – 97 (47) 42 (53) 0.43
Concomitant PCI 75 (17) – 58 (28) 17 (21) 0.43
Staged PCI 63 (14) – 38 (18) 25 (31) 0.41
New-onset of atrial fibrillation 33 (7) 12 (8) 16 (8) 5 (6) 0.91
Post TAVI—need for PPM 107 (24) 42 (27) 43 (21) 22 (28) 0.32
Valve in series 9 (2) 4 (3) 2 (1) 3 (4) 0.28
Revascularization (%)
PCI 139 (31) – 97 (47) 42 (53) 0.43
Vessels treated
Left main 10 (7) – 4 (4) 6 (14) 0.07
Left anterior descending 83 (60) – 60 (62) 23 (55) 0.46
Left circumflex 25 (18) – 15 (16) 10 (24) 0.34
Right coronary artery 53 (38) – 36 (37) 17 (40) 0.71
Vein graft 5 (4) – 1 (1) 4 (10) 0.029
Residual SYNTAX score 9.2+10.9 – 4.0+4.4 21.2+12.0 ,0.001
Values are n (%). CAD, coronary artery disease; PCI, percutaneous coronary intervention; PPM, permanent pacemaker; TAVI, transcatheter aortic valve implantation; VARC, Valve
Academic Research Consortium.
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P-value RR (95% CI) P-value
Events at 30 days
Cardiovascular death, stroke,
or MI
34 (7.6) 11 (7.0) 15 (7.2) 8 (10.0) 1.04 (0.48–2.26) 0.93 1.44 (0.58–3.58) 0.43 0.47
All-cause death, stroke, or MI 38 (8.5) 12 (7.6) 18 (8.7) 8 (10.0) 1.14 (0.55–2.37) 0.73 1.32 (0.54–3.23) 0.54 0.54
All-cause death 28 (6.3) 8 (5.1) 14 (6.8) 6 (7.5) 1.35 (0.57–3.23) 0.49 1.52 (0.53–4.39) 0.44 0.41
Cardiovascular death 23 (5.2) 6 (3.8) 11 (5.4) 6 (7.5) 1.42 (0.52–3.83) 0.49 2.03 (0.65–6.29) 0.22 0.22
Stroke 14 (3.2) 8 (5.1) 4 (2.0) 2 (2.6) 0.38 (0.11–1.26) 0.12 0.50 (0.11–2.33) 0.37 0.19
Major stroke 13 (3.0) 8 (5.1) 3 (1.5) 2 (2.6) 0.28 (0.08–1.07) 0.06 0.50 (0.11–2.33) 0.37 0.15
Minor stroke 1 (0.2) 0 (0.0) 1 (0.5) 0 (0.0) – – – – –
Myocardial infarction 2 (0.5) 1 (0.6) 1 (0.5) 0 (0.0) 0.76 (0.05–12.21) 0.85 – – –
Acute kidney injury 17 (3.8) 6 (3.8) 6 (2.9) 5 (6.3) 0.76 (0.25–2.32) 0.64 1.65 (0.52–5.24) 0.40 0.54
Major access site complications 38 (8.5) 14 (8.9) 20 (9.7) 4 (5.0) 1.09 (0.57–2.09) 0.89 0.56 (0.19–1.66) 0.30 0.39
VARC safety endpoint 114 (25.6) 38 (24.1) 54 (26.1) 22 (27.5) 1.08 (0.76–1.55) 0.66 1.14 (0.73–1.80) 0.56 0.54
Events at 1 year
Cardiovascular death, stroke,
or MI 67 (17.3) 18 (12.5) 29 (16.1) 20 (29.6) 1.23 (0.68–2.21) 0.49 2.24 (1.18–4.23) 0.013 0.016
All-cause death, stroke, or MI 89 (23.0) 27 (19.4) 39 (21.5) 23 (33.5) 1.10 (0.68–1.80) 0.69 1.73 (0.99–3.01) 0.054 0.07
All-cause death 76 (19.9) 23 (16.9) 35 (19.6) 18 (26.1) 1.18 (0.70–2.00) 0.53 1.58 (0.85–2.94) 0.14 0.16
Cardiovascular death 50 (13.1) 12 (8.6) 24 (13.6) 14 (20.4) 1.55 (0.78–3.10) 0.22 2.36 (1.09–5.10) 0.029 0.029
Stroke 18 (4.5) 8 (5.1) 6 (3.3) 4 (6.7) 0.57 (0.20–1.65) 0.30 1.00 (0.30–3.32) 1.00 0.79
Major stroke 17 (4.3) 8 (5.1) 5 (2.9) 4 (6.7) 0.48 (0.16–1.46) 0.19 1.00 (0.30–3.32) 1.00 0.74
Minor stroke 1 (0.2) 0 (0.0) 1 (0.5) 0 (0.0) – – – – –
Myocardial infarction 6 (1.8) 2 (1.5) 2 (1.1) 2 (4.0) 0.77 (0.11–5.47) 0.80 2.00 (0.28–14.21) 0.49 0.54










Figure 1 Cardiovascular death, stroke, or myocardial infarction through one year according to coronary artery disease (CAD) severity. Cumu-
lative event curves of the primary endpoint—the composite of cardiovascular death, stroke, and myocardial infarction—in patients without CAD,
patients with low SYNTAX score (SS; 0–22), and patients with high SS (.22).
Figure2 Cardiovascular death through one year according to CAD severity. Cumulative event curves of cardiovascular death in patients without
CAD, patients with low SYNTAX score (SS; 0–22), and patients with high SS (.22).
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higher baseline risk anddegreeofCADseveritywasparalleledbya gra-
dient in the logistic EuroSCORE and STS score ranging from 19.5 and
5.9, respectively, inpatientswithoutCAD,upto30.3and8.6 inpatients
with high SS. Of note, patients with more severe CAD had a greater
aortic valve area and a lower mean transaortic gradient at baseline.
Similar findings have been reported among patients with severe AS
undergoing SAVR.5 It is tempting to speculate that more advanced
CAD is responsible for an earlier manifestation of clinical symptoms
resulting in earlier valve replacement therapy among patients with
severe AS. Future studies will need to confirm whether this hypothesis
holds true in larger patient populations.
Coronary artery disease and need for concomitant CABG has
been shown to adversely influence short- and long-term outcomes
of patients with severe AS undergoing SAVR.5,6 However, elderly
patients with severe AS undergoing TAVI are frequently not consid-
ered suitable candidates for SAVR due to a high or excessive baseline
risk.27,28 It is therefore debated whether CAD extent and complexity
has an impact on clinical outcomes among these patients, or whether
the valvular disease and comorbid conditions play a predominant
role, camouflaging any prognostic impact of CAD. Dewey et al.8
reported a significantly higher 1-year mortality among 84 patients
with CAD compared with 87 patients without CAD after TAVI
(35.7 vs. 18.4%, P ¼ 0.01). Similarly, the presence of CAD has been
identified as an independent predictor of death (HR: 1.38, 95% CI:
1.07–1.76) in the large-scale multicentre post-approval SOURCE
XT TAVI registry.29 Conversely, Masson et al.10 reported no impact
of CAD on survival among 136 patients undergoing TAVI during
1-year follow-up, despite numerically higher event rates in patients
with than in those without CAD (27.7 vs. 18.8%, P ¼ 0.63). Along
this line, D’Ascenzo et al.12 performed a meta-analysis of seven ob-
servational studies, suggesting that CAD does not increase the risk
of death in patients undergoing TAVI (OR: 1.0, 95% CI: 0.67–1.50).
It is noteworthy that the anatomic extent and complexity of
CAD—as systematically quantified by the use of the SS—and its
impact on ischaemic outcomes has not been previously assessed in
this patient population. Therefore, the present study represents
the first analysis evaluating the impact of CAD extent and complexity
among elderly patients with severe AS undergoing TAVI, and our
findings suggest that CAD severity is associated with more frequent
ischaemic events at 1 year. Event rates of the primary endpoint, of
all-cause death, of cardiovascular death, and of the composite of all-
cause death, stroke, and MI, increased along with CAD severity.
Specifically, patients with SS .22 had a markedly higher risk of the
composite of cardiovascular death, stroke, and MI at 1 year, primarily
due to a two-fold increased risk of cardiovascular death. Of note, the
thresholdof22 for SS, asdescribed in the SYNTAXtrial,14 is currently
used as key exclusion criteria in the SURgical replacement and Trans-
catheter Aortic Valve Implantation (SURTAVI) trial, in which TAVI is
compared with SAVR among patients with severe AS at intermediate
surgical risk (ClinicalTrials.gov identifier NCT01586910). Similarly,
SS is used for exclusion in the ongoing Placement of AoRTic TraNs-
cathetER Valves 2 (PARTNER-2) trial (ClinicalTrials.gov identifier
NCT01314313), with a higher threshold of SS .32.
Using multivariate analysis, CAD with SS.22 was associated with
a nominal 70% increase in the risk of cardiovascular death, stroke, or
MI at 1 year, however, without reaching statistical significance. This
Figure 3 Predictors of cardiovascular death, stroke, or myocardial infarction at one year. LVEF, left ventricular ejection fraction.
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may be explained by the extent of comorbid conditions among
patients with severe CAD and other risk factors, particularly
impaired left ventricular function which was identified as the only in-
dependent predictor of the composite primary endpoint at 1 year in
our study.
In the present study, patients with higher baseline SS undergoing
TAVI received less complete revascularization as indicated by higher
rSS, and experienced less favourable clinical outcomes at 1 year.
Although concomitant CABG among patients undergoing SAVR is
associated with increased peri-operative mortality, complete revascu-
larization is usually performed bypassing all lesions with a diameter
stenosis .50–70%. In this context, a recent propensity-score-
matched comparison between patients undergoing CABG plus
SAVR and patients undergoing isolated SAVR reported similar short-
and long-term survival, suggesting that CABG with complete revascu-
larization at the time of SAVR offsets the adverse effects associated
withCADamongpatientswithotherwise similarcomorbidities.5 Con-
versely, van Mieghem et al.30 recently reported that completeness of
revascularization did not impact clinical outcomes in a series of 124
TAVI patients with significant CAD who underwent PCI in 32% of
cases based on Heart Team decision. This study indicated that a judi-
cious revascularization strategy can generate favourable mid-term
outcome obviating the need for complete coronary revascularization
among appropriately selected TAVI patients. Along this line, our find-
ings suggest that incomplete revascularization with high rSS (.14)
impairs long-term clinical outcomes after TAVI, whereas lower rSS
(0–14)—indicating an acceptable extent of residual CAD after
PCI—may be associated with outcomes comparable with complete
revascularization. It is also important to note that patients undergoing
SAVR are typically younger and suffer from fewer comorbidities than
patients undergoing TAVI and that the long-term benefit derived







































































































































































































































































































































































































































































































































































































Figure 4 Correlation between the SYNTAX-score at baseline
(x-axis) and residual SYNTAX-score (y-axis). Residual SYNTAX-
score was defined as SYNTAX-score remaining after percutaneous
coronary interventions prior to transcatheter aortic valve implant-
ation. For patients not undergoing percutaneous coronary inter-
ventions, residual SYNTAX score was equivalent to SYNTAX
score at baseline.
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younger patients. However, randomized trials with prospective plan-
ning of revascularization strategy are required to address the optimal
revascularization strategy among patients undergoing TAVI.
Several limitations need to be considered when interpreting our
study. First, this is a single-centre, observational study and therefore
our results need to be considered as hypothesis generating.
However, the close correlation of CAD with baseline characteristics
and well-established risk factors for CAD together with the size of
the study and the event rates lend strength to the analysis. Secondly,
patients were stratified into three groups based on the presence and
severity of CAD as assessed by the SS. This retrospective stratifica-
tion neglects that treatment allocation was based on clinical judge-
ment, therefore introducing a source of performance bias. Thirdly,
SS is an anatomical risk score based on visual estimation of coronary
angiograms with inherent limitations.31 For the purpose of the
present analysis, SSwerecalculatedby consensusof twoexperienced
invasive cardiologists trained for SS assessment with evidence of
good reproducibility and blinded to clinical outcomes. It cannot be
excluded, however, that results may have varied if less experienced
readers had determined SS.20 Finally, it needs to be pointed out
that the objective of the present study was to evaluate whether the
extent and complexityof CAD atbaseline hadan impact on ischaemic
clinical outcomes after TAVI, irrespective of coronary revasculariza-
tion. However,we observed thatpatients with higherSS received less
complete revascularization and therefore had a higher extent and
complexity of CAD also after PCI prior to TAVI compared with
patients with low SS. Patients with less complete revascularization
(i.e. those with higher rSS) had a higher risk of cardiovascular
death, stroke, or MI at 1 year. This observation corroborates that
more severe and complex CAD impairs clinical outcomes after TAVI.
Conclusions
Severity of CAD appears to be associated with impaired clinical out-
comes at 1 year after TAVI. Patients with SS .22 receive less com-
plete revascularization and have a higher risk of cardiovascular
death, stroke, or MI than patients without CAD or low SS.
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